Longer-Lasting “On” Time per Dose

In the past few decades, levodopa therapy has evolved to provide longer-lasting benefits for patients with Parkinson’s disease. The development of RYTARY has lead to reduced “off” time and more “on” time. In this article, Robert A. Hauser, MD, MBA, FAAN, and John C. Morgan, MD, PhD, review the results of a post hoc analysis on the duration of benefit per dose with RYTARY.

View More
Related Publication

Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)

Hauser RA, et al. Jan 2021
View Publication

Video Library

See more